Eisai Co., Ltd. (OTCMKTS:ESALY – Get Free Report)’s stock price passed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $61.51 and traded as low as $61.00. Eisai shares last traded at $61.51, with a volume of 331,800 shares traded.
Eisai Stock Performance
The company has a market capitalization of $17.64 billion, a P/E ratio of 70.70, a price-to-earnings-growth ratio of 2.46 and a beta of 0.31. The business has a 50 day moving average of $61.51 and a 200 day moving average of $61.51. The company has a quick ratio of 1.77, a current ratio of 2.20 and a debt-to-equity ratio of 0.10.
About Eisai
Eisai Co, Ltd. is a Japanese pharmaceutical company headquartered in Tokyo. The company researches, develops, manufactures and markets prescription medicines, with a focus on neurology, oncology and treatments for dementia. Eisai also develops selected medicines for areas including sleep disorders, epilepsy and gastrointestinal conditions.
Its products include Leqembi (lecanemab), a treatment for early Alzheimer’s disease developed in collaboration with Biogen, as well as Aricept (donepezil), Fycompa (perampanel), Dayvigo (lemborexant), Halaven (eribulin) and Lenvima (lenvatinib), which was developed with Merck in certain markets.
Further Reading
- Five stocks we like better than Eisai
- 3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note
- 3 AI Winners, 3 Very Different Paths to Higher Margins
- Plexus Is Booming—But Can the Growth Story Last?
- Conagra’s Turnaround Is Starting to Show Up in the Numbers
Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.
